uniQure N.V.
Open
$27.65
Prev. Close
$27.68
High
$27.69
Low
$27.53
Market Snapshot
$1.72B
-8.3
-4.93
$27.12M
221
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company employs 221 full-time employees The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company employs 221 full-time employees The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Recently from Cashu
uniQure N.V. Faces Class Action Lawsuits Over Alleged Investor Misleading Communications
uniQure N.V. Faces Class Action Lawsuits Over Alleged Misleading Statements uniQure N.V. finds itself embroiled in multiple class action lawsuits filed by law firms representing investors who believe…
uniQure N.V. Faces Class Action Lawsuit Over Huntington's Disease Drug Misrepresentations
uniQure Faces Legal Challenges Over Misleading Statements Regarding Huntington's Disease Drug uniQure N.V. is currently embroiled in a class action lawsuit that raises significant concerns about its c…
Class Action Against uniQure N.V. Over Alleged Drug Approval Misrepresentation
uniQure Faces Class Action Over Alleged Misrepresentation in Drug Approval Process Rosen Law Firm, a prominent figure in investor rights advocacy, has issued a vital reminder regarding a class action…
Legal Challenges Threaten uniQure’s Gene Therapy Reputation and Investor Confidence
### Legal Challenge Poses Questions for uniQure's Gene Therapy Developments uniQure N.V., a biopharmaceutical company renowned for its innovative approaches to rare diseases, finds itself embroiled in…